Mangrove Partners’s Immix Biopharma IMMX Stock Holding History

Mangrove Partners’s Portfolio IMMX Stock Details IMMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-23,772	Closed	-$217K	–	507
2026 Q1	$217K	Buy	+23,772	New	+$175K	0.02%	346

Other funds holding IMMX

Jupiter Topco New York $245B AUM

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Mangrove Partners's IMMX Position: Q2 2026 in Review

Mangrove Partners sold out of Immix Biopharma (IMMX) in Q2 2026, closing a stake of 23,772 shares — an estimated $217K sold.

Mangrove Partners first reported a position in IMMX in Q1 2026 and held it in 1 quarter. The position peaked at $217K in Q1 2026. 109 funds tracked by Wall St. Rank hold IMMX as of Q2 2026.

Mangrove Partners reported no remaining Immix Biopharma position as of Q2 2026 after selling out during the quarter.
Mangrove Partners sold 23,772 Immix Biopharma shares in Q2 2026, an estimated $217K.
Mangrove Partners first reported a position in Immix Biopharma in Q1 2026 and held it in 1 quarter.
Mangrove Partners's Immix Biopharma position peaked at $217K in Q1 2026.
109 funds tracked by Wall St. Rank held Immix Biopharma as of Q2 2026.

Based on Mangrove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.